Section Arrow
TNGX.NASDAQ
- Tango Therapeutics
Quotes are at least 15-min delayed:2026/01/05 04:52 EST
Pre Market
Last
 8.93
0 (0.00%)
Bid
8.92
Ask
10
High 9.28 
Low 8.93 
Volume 128 
Regular Hours (Closed)
Last
 8.93
+0.07 (+0.79%)
Day High 
9.16 
Prev. Close
8.86 
1-M High
10.45 
Volume 
1.16M 
Bid
8.92
Ask
10
Day Low
8.73 
Open
8.85 
1-M Low
8.3 
Market Cap 
1.19B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 8.65 
20-SMA
50-SMA 8.75 
52-W High 11.2 
52-W Low 1.03 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.91/-1.32
Enterprise Value
1.22B
Balance Sheet
Book Value Per Share
1.19
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
42.07M
Operating Revenue Per Share
0.28
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OTLKOutlook Therapeutics0.66-0.92-58.23%0.58PE
Pre Market 0.6845 +0.0245 +3.71%
MREOMereo BioPharma Group plc0.5104+0.0937+22.49%-- 
Pre Market 0.5539 +0.0435 +8.52%
SLSSELLAS Life Sciences Group4.35+0.58+15.38%-- 
Pre Market 4.81 +0.46 +10.57%
ASBPAspire Biopharma Holdings Inc.0.1369+0.005+3.79%-- 
Pre Market 0.1421 +0.0052 +3.80%
RXRXRecursion Pharmaceuticals4.2+0.11+2.69%-- 
Pre Market 4.28 +0.08 +1.90%
Industry overview quotes are at least 15 minutes delayed
Business Description
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNScancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.